Loading…
Loading…
TNGNQ does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for TNGNQ and 80,000+ other tickers.
See exactly how TNGNQ's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TNGNQ and 80,000+ other tickers.
Tengion, Inc. was a biotechnology company focused on regenerative medicine, established in 2003 and headquartered in Winston-Salem, North Carolina. Its primary objective was the discovery, development, manufacturing, and commercialization of advanced cellular therapeutic products, often termed "neo-organs." These innovations, comprising living cells sometimes combined with synthetic or natural supporting materials, were intended for implantation or injection into the body to integrate, regenerate, or substitute for compromised tissues or organs. The company's product pipeline included two…
No recent news available.